AKRO News and Press, Akero Therapeutics Inc. From 03/17/23

2023-03-17 07:07:14 ET Akero Therapeutics press release ( NASDAQ: AKRO ): Q4 GAAP EPS of -$0.49 beats by $0.31 . Akero's cash, cash equivalents and short-term marketable securities for the year ended December 31, 2022 were $351.4 million. Akero believes that its ca...

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full...

Summary Genfit is a relatively low-beta play offering investors tactical upside with a potential re-rating to the upside. Investors have rewarded the company's pipeline assets to date, in addition to emerging data from its non-invasive technologies. Market generated data is supporti...

Summary Akero caught a strong bid last year following positive top-line data from its HARMONY study. The company is aiming to provide a potential medical breakthrough in the treatment of nonalcoholic steatohepatitis. Investors have paused the rally for now, and additional catalysts ...

Summary Biotech stocks have pulled back and offer better risk to reward for investors, Direxion Daily S&P Biotech Bull 3x Shares ETF is a popular way to trade them. M&A is likely to drive prices for mid-cap and small-cap biopharma. Using a leveraged ETF like LABU is risky, e...

Summary Small caps outperformed the Nasdaq Composite last year as stocks fell due to the Federal Reserve's efforts to control inflation. Market fears are mounting that the economy may slip into a recession, but there are opportunities in small-cap stocks. The potential risk of a lon...

Morgan Stanley raised its recommendation on Akero Therapeutics ( NASDAQ: AKRO ) to Overweight from Equal Weight on Friday, citing the company’s potential against liver disease nonalcoholic steatohepatitis (NASH) The analyst Michael Ulz argues that the Phase 2 data Akero ( AKR...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as...

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...